E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Following the latest approvals in India and Taiwan, GC Biopharma’s Hunter syndrome treatment, Hunterase IV, is now authorized in 14 countries.
imphoenix82
Powered by Signia’s Acoustic Intelligence, the new AI hearing aid platform continuously analyses multiple dimensions of sound—including speech, noise, environmental conditions and the wearer’s own voice—enabling hearing to adapt to the full listening experience, not just the noise.
imphoenix82
The reforms amend the Medical Devices Rules, 2017 to simplify outsourced sterilization, standardize testing fees and recognize the EU for waiver of clinical investigation requirements.
imphoenix82
Modern diabetic foot care includes structured neurological and vascular evaluation, angiosome-based assessment and evidence-based wound management approaches that support early intervention and help reduce the risk of serious complications.
imphoenix82
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
imphoenix82
Patients and Industry experts are calling for full insurance coverage of prosthetic and orthotic services to help more amputees lead independent lives and contribute to the country’s economy.
dineshwori
Under the new agreement, Henlius will grant Sandoz exclusive rights to register and commercialize up to 10 partnered products outside China
imphoenix82
With the unit classified as VAI, Aurobindo Pharma said pending applications for multiple inhalers and other dosage forms filed from the facility can now progress through the USFDA’s review process.
imphoenix82
Redcliffe Labs and Skyroot Aerospace’s first mission, DRIFT-1, will test dry diagnostic reagents in low Earth orbit for 90 days.
imphoenix82
Lilly is calling on regulators, customs agencies, law enforcement authorities, online platforms, and payment companies to shut down the illegal retatrutide black market.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
